市場調查報告書

化膿性汗腺炎(HS)- 流行病學預測 2030年

Hidradenitis Suppurativa (HS) - Epidemiology Forecast to 2030

出版商 DelveInsight Business Research LLP 商品編碼 928278
出版日期 內容資訊 英文 100 Pages
商品交期: 最快1-2個工作天內
價格
化膿性汗腺炎(HS)- 流行病學預測 2030年 Hidradenitis Suppurativa (HS) - Epidemiology Forecast to 2030
出版日期: 2020年03月01日內容資訊: 英文 100 Pages
簡介

本報告提供主要7個國家(美國、英國、德國、法國、義大利、西班牙、日本)的化膿性汗腺炎(HS)市場相關調查,疾病概要,主要7個國家的市場趨勢,流行病學的預測,患病數的變化與預測等資訊。

目錄

第1章 主要洞察

第2章 摘要整理

第3章 SWOT分析

第4章 患者分佈

  • 患者分佈的變化與預測

第5章 市場概要

  • 市場佔有率(實際成果值)
  • 市場佔有率(預測值)

第6章 疾病概要

  • 簡介
  • 徵兆與症狀
  • 分類和重病度的評估
  • 診斷

第7章 流行病學和患者數

  • 主要調查結果
  • 假設和根據:主要7個國家
  • 主要7個國家的整體患病數
  • 患病數:性別
  • 患病數:各年齡
  • 患病數:各分期(重病度)
  • 治療完畢患者數

第8章 各國流行病學

  • 美國
  • 歐洲5個國家
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 英國
  • 日本

第9章 附錄

第10章 DelveInsight的服務內容

第11章 免責聲明

第12章 關於DelveInsight

目錄
Product Code: DIEI0877

Overview

DelveInsight's 'Hidradenitis Suppurativa (HS) - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Hidradenitis Suppurativa epidemiology in the 7MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Hidradenitis Suppurativa (HS) Understanding

According to the National Organization of Rare Disorders, HS is a chronic condition characterized by swollen, painful lesions, occurring in the armpit, groin, anal and breast regions. It is painful and long-term skin condition causing abscesses and scarring on the skin. Affected patients may present with acute abscesses, but the condition often progresses to a chronic state with persistent pain, sinus tract fistula formation, and scarring. Although foreign body type granulomas are a common finding in HS, the presence of discrete epithelioid granulomas in the dermis away from the site of active inflammation is unusual and should alert the pathologist to the possibility of a systemic granulomatous disease like Crohn's disease (CD) or sarcoidosis. The longstanding disease can result in fibrosis, dermal contractures, significant scarring, the formation of fistulae, and rarely malignant transformation to squamous cell carcinoma

Hidradenitis Suppurativa (HS) Epidemiology Perspective by DelveInsight

The HS epidemiology division provides the insights about historical and current patient pool and forecasted trend for each seven major countries. The HS epidemiology data are studied through HS possible division to give a better understanding of the Disease scenario in 7MM. The HS epidemiology is segmented by Total Prevalent Patient Population, Diagnosed Prevalent Patient Population, Age-specific Diagnosed Prevalent Patient Population, Gender-specific Diagnosed Prevalent Patient Population, Stage-Specific (Severity-specific) Prevalent Population, and Treated Prevalent Cases of HS covering the US, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Hidradenitis Suppurativa Detailed Epidemiology Segmentation

The HS epidemiology covered in the report provides historical as well as forecasted epidemiology {Total Diagnosed Prevalent Cases, Age-specific Diagnosed Prevalent Cases, Gender-specific Diagnosed Prevalent Cases, Stage-Specific prevalent Cases, and Treated Prevalent Cases of HS} scenario of HS in the 7MM covering United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2017 to 2030.

The DelveInsight HS report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report

  • The HS report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The HS Report and Model provide an overview of the risk factors and global trends of HS in the seven major markets (7MM: US, Germany, France, Italy, Spain, and the United Kingdom, and Japan)
  • The report provides insight about the historical and forecasted patient pool of HS in seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of HS
  • The report provides the segmentation of the HS epidemiology by Age-specific diagnosed prevalent Cases of HS in 7MM
  • The report provides the segmentation of the HS epidemiology by Gender-specific diagnosed prevalent Cases of HS in 7MM
  • The report provides the segmentation of the HS epidemiology by Stage-Specific diagnosed prevalent Cases of HS in 7MM

Report Highlights

  • 11-Year Forecast of Hidradenitis Suppurativa epidemiology
  • 7MM Coverage
  • Total Diagnosed prevalent Cases of Hidradenitis Suppurativa
  • Diagnosed Prevalent Cases according to segmentation: Gender-specific, Age-specific, Stage-specific Incidence
  • Treated cases of Hidradenitis Suppurativa

KOL-Views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the over HS scenario of the indications.

Key Questions Answered

  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Hidradenitis Suppurativa?
  • What are the key findings pertaining to the Hidradenitis Suppurativa epidemiology across 7MM and which country will have the highest number of patients during the study period (2017-2030)?
  • What would be the total number of patients of Hidradenitis Suppurativa across the 7MM during the study period (2017-2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the study period (2017-2030)?
  • At what CAGR the patient population is expected to grow in 7MM during the study period (2017-2030)?
  • What is the disease risk, burden and unmet needs of the Hidradenitis Suppurativa?
  • What are the current available treatments of Hidradenitis Suppurativa?

Reasons to buy

The Hidradenitis Suppurativa Epidemiology report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the global Hidradenitis Suppurativa market
  • Quantify patient populations in the global Hidradenitis Suppurativa market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Hidradenitis Suppurativa therapeutics in each of the markets covered
  • Understand the magnitude of Hidradenitis Suppurativa population by its severity
  • The Hidradenitis Suppurativa epidemiology report and model were written and developed by Masters and PhD level epidemiologists
  • The Hidradenitis Suppurativa Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Most of the HS cases remain underdiagnosed, the diagnosed prevalent population of HS in Seven major markets was 1,210,785 in 2017 which is anticipated to increase by 2030. The estimates show highest diagnosed prevalent population of HS is in the United States. Among the European 5 countries, the Germany had highest diagnosed prevalent population of HS, followed by France, and the United Kingdom. On the other hand, Spain had the lowest prevalent population of HS in 2017.

As per DelveInsight's analysis, a higher percentage of diagnosed prevalence was observed for females, in comparison to males, in all the 7MM countries and highest proportion of HS cases were observed in 30-39 years age group among all the countries. It has been observed that Severe HS cases are comparatively very less from mild and moderate cases

Table of Contents

1. Key Insights

2. Executive Summary: Hidradenitis Suppurativa (HS)

3. SWOT Analysis: Hidradenitis Suppurativa (HS)

4. Hidradenitis Suppurativa (HS) Patient Share (%) Overview at a Glance

  • 4.1. Patient Share (%) Distribution of Hidradenitis Suppurativa in 2017 and 2030

5. Hidradenitis Suppurativa Market Overview at a Glance

  • 5.1. Market Share (%) Distribution of Hidradenitis Suppurativa in 2017
  • 5.2. Market Share (%) Distribution of Hidradenitis Suppurativa in 2030

6. Disease Overview: Hidradenitis Suppurativa (HS)

  • 6.1. Introduction
  • 6.2. Causes and Symptoms of Hidradenitis Suppurativa (HS)
  • 6.3. Classification and Severity Assessment of Hidradenitis Suppurativa (HS)
    • 6.3.1. Hurley Stages of HS
    • 6.3.2. Modified Sartorius Score (MSS) of HS
    • 6.3.3. Physician Global Assessment of Hidradenitis Suppurativa (HS-PGA)
    • 6.3.4. Specific Severity Index of Hidradenitis Suppurativa (HSSI)
    • 6.3.5. Pathophysiology of Hidradenitis Suppurativa
    • 6.3.6. Genetic Basis of Hidradenitis Suppurativa (HS)
  • 6.4. Diagnosis of Hidradenitis Suppurativa (HS)
    • 6.4.1. Differential Diagnoses
    • 6.4.2. Biomarkers of Hidradenitis Suppurativa (HS)
    • 6.4.3. Risk Factors and Complications
    • 6.4.4. Comorbidities

7. Epidemiology and Patient Population

  • 7.1. Key Findings
  • 7.2. Assumptions and Rationale: 7MM
  • 7.3. Total Prevalent Patient Population of HS in the 7MM
  • 7.4. Total Diagnosed Prevalent Patient Population of HS in the 7MM
  • 7.5. Gender-Specific Prevalent Patient Population of HS in the 7MM
  • 7.6. Age-Specific Prevalent Patient Population of HS in the 7MM
  • 7.7. Stage-Specific (Severity-specific) prevalent cases of HS in the 7MM
  • 7.8. Treated Prevalent Cases of HS in the 7MM

8. Country-wise Epidemiology of HS in the 7MM

  • 8.1. United States
    • 8.1.1. Total Diagnosed Prevalent cases of HS in the United States
    • 8.1.2. Gender-Specific Prevalent cases of HS in the United States
    • 8.1.3. Age-Specific Prevalent cases of HS in the United States
    • 8.1.4. Stage-Specific Prevalent Cases of HS in the United States
    • 8.1.5. Treated Prevalent Cases of HS in the United States
  • 8.2. EU5
    • 8.2.1. Germany
      • 8.2.1.1. Total Diagnosed Prevalent cases of HS in Germany
      • 8.2.1.2. Gender-Specific Prevalent cases of HS in Germany
      • 8.2.1.3. Age-Specific Prevalent cases of HS in Germany
      • 8.2.1.4. Stage-Specific Prevalent Cases of HS in Germany
      • 8.2.1.5. Treated Prevalent Cases of HS in Germany
    • 8.2.2. France
      • 8.2.2.1. Total Diagnosed Prevalent cases of HS in France
      • 8.2.2.2. Gender-Specific Prevalent cases of HS in France
      • 8.2.2.3. Age-Specific Prevalent cases of HS in France
      • 8.2.2.4. Stage-Specific Prevalent Cases of HS in France
      • 8.2.2.5. Treated Prevalent Cases of HS in France
    • 8.2.3. Italy
      • 8.2.3.1. Total Diagnosed Prevalent cases of HS in Italy
      • 8.2.3.2. Gender-Specific Prevalent cases of HS in Italy
      • 8.2.3.3. Age-Specific Prevalent cases of HS in Italy
      • 8.2.3.4. Stage-Specific Prevalent Cases of HS in Italy
      • 8.2.3.5. Treated Prevalent Cases of HS in Italy
    • 8.2.4. Spain
      • 8.2.4.1. Total Diagnosed Prevalent cases of HS in Spain
      • 8.2.4.2. Gender-Specific Prevalent cases of HS in Spain
      • 8.2.4.3. Age-Specific Prevalent cases of HS in Spain
      • 8.2.4.4. Stage-Specific Prevalent Cases of HS in Spain
      • 8.2.4.5. Treated Prevalent Cases of HS in Spain
    • 8.2.5. United Kingdom
      • 8.2.5.1. Total Diagnosed Prevalent cases of HS in the United Kingdom
      • 8.2.5.2. Gender-Specific Prevalent cases of HS in the United Kingdom
      • 8.2.5.3. Age-Specific Prevalent cases of HS in the United Kingdom
      • 8.2.5.4. Stage-Specific Prevalent Cases of HS in the United Kingdom
      • 8.2.5.5. Treated Prevalent Cases of HS in the United Kingdom
  • 8.3. Japan
    • 8.3.1. Total Diagnosed Prevalent cases of HS in Japan
    • 8.3.2. Gender-Specific Prevalent cases of HS in Japan
    • 8.3.3. Age-Specific Prevalent cases of HS in Japan
    • 8.3.4. Stage-Specific Prevalent Cases of HS in Japan
    • 8.3.5. Treated Prevalent Cases of HS in Japan

9. Appendix

  • 9.1. Bibliography
  • 9.2. Report Methodology

10. Disclaimer

11. DelveInsight Capabilities

12. About DelveInsight

List of Tables

  • Table 1 Summary of Hidradenitis Suppurativa (HS) Market, Epidemiology, and Key Events (2017-2030)
  • Table 2 Hurley Staging System
  • Table 3 Modified Sartorius Score of Hidradenitis Suppurativa
  • Table 4 Physician Global Assessment of Hidradenitis Suppurativa (HS-PGA)
  • Table 5 Specific Severity Index of Hidradenitis Suppurativa (HSSI)
  • Table 6 Differential Diagnosis of Hidradenitis Suppurativa
  • Table 7 Summary of Sources Explored for the Epidemiology of HS
  • Table 8 Total Prevalent Cases of HS in the 7MM (2017-2030)
  • Table 9 Total Diagnosed Prevalent Cases of HS in the 7MM (2017-2030)
  • Table 10 Gender-Specific Prevalent Cases of HS in the 7MM (2017-2030)
  • Table 11 Age-Specific Prevalent Cases of HS in the 7MM (2017-2030)
  • Table 12 Stage-Specific Prevalent Cases of HS in in the 7MM (2017-2030)
  • Table 13 Treated Prevalent Cases of HS in the 7MM (2017-2030)
  • Table 14 Total Prevalent Cases of HS in the United States (2017-2030)
  • Table 15 Gender-Specific Prevalent Cases of HS in Germany (2017-2030)
  • Table 16 Age-Specific Prevalent Cases of HS in the United States (2017-2030)
  • Table 17 Stage-Specific Prevalent Cases of HS in the United States (2017-2030)
  • Table 18 Treated Prevalent Cases of HS in the United States (2017-2030)
  • Table 19 Total Prevalent Cases of HS in Germany (2017-2030)
  • Table 20 Gender-Specific Prevalent Cases of HS in Germany (2017-2030)
  • Table 21 Age-Specific Prevalent Cases of HS in Germany (2017-2030)
  • Table 22 Stage-Specific Prevalent Cases of HS in Germany 2017-2030)
  • Table 23 Treated Prevalent Cases of HS in Germany (2017-2030)
  • Table 24 Total Prevalent Cases of HS in France (2017-2030)
  • Table 25 Gender-Specific Prevalent Cases of HS in France (2017-2030)
  • Table 26 Age-Specific Prevalent Cases of HS in France (2017-2030)
  • Table 27 Stage-Specific Prevalent Cases of HS in France 2017-2030)
  • Table 28 Treated Prevalent Cases of HS in France (2017-2030)
  • Table 29 Total Diagnosed Prevalent Cases of HS in Italy (2017-2030)
  • Table 30 Gender-Specific Prevalent Cases of HS in Italy (2017-2030)
  • Table 31 Age-Specific Prevalent Cases of HS in Italy (2017-2030)
  • Table 32 Stage-Specific Prevalent Cases of HS in Italy 2017-2030)
  • Table 33 Treated Prevalent Cases of HS in Italy (2017-2030)
  • Table 34 Total Diagnosed Prevalent Cases of HS in Spain (2017-2030)
  • Table 35 Gender-Specific Prevalent Cases of HS in Spain (2017-2030)
  • Table 36 Age-Specific Prevalent Cases of HS in Spain (2017-2030)
  • Table 37 Stage-Specific Prevalent Cases of HS in Spain (2017-2030)
  • Table 38 Treated Prevalent Cases of HS in Spain (2017-2030)
  • Table 39 Total Diagnosed Prevalent Cases of HS in the United Kingdom (2017-2030)
  • Table 40 Gender-Specific Prevalent Cases of HS in the United Kingdom (2017-2030)
  • Table 41 Age-Specific Prevalent Cases of HS in the United Kingdom (2017-2030)
  • Table 42 Stage-Specific Prevalent Cases of HS in the United Kingdom 2017-2030)
  • Table 43 Treated Prevalent Cases of HS in the United Kingdom (2017-2030)
  • Table 44 Total Diagnosed Prevalent Cases of HS in Japan (2017-2030)
  • Table 45 Gender-Specific Prevalent Cases of HS in Japan (2017-2030)
  • Table 46 Age-Specific Prevalent Cases of HS in Japan (2017-2030)
  • Table 47 Stage-Specific Prevalent Cases of HS in Japan 2017-2030)
  • Table 48 Treated Prevalent Cases of HS in Japan (2017-2030)

List of Figures

  • Figure 1 Hidradenitis Suppurativa (HS) SWOT Analysis
  • Figure 2 Disease Burden in the Patient with HS
  • Figure 3 Stages of Hidradenitis Suppurativa
  • Figure 4 Pathophysiology of HS
  • Figure 5 An approach to the Diagnosis of Hidradenitis Suppurativa
  • Figure 6 Risk Factors of HS
  • Figure 7 Comorbidities in HS
  • Figure 8 Total Prevalent Cases of HS in the 7MM (2017-2030)
  • Figure 9 Total Diagnosed Prevalent Cases of HS in the 7MM (2017-2030)
  • Figure 10 Age-specific Prevalent Cases of HS in the 7MM (2017-2030)
  • Figure 11 Age-Specific Prevalent Cases of HS in the 7MM (2017-2030)
  • Figure 12 Stage-Specific Prevalent Cases of HS in in the 7MM (2017-2030)
  • Figure 13 Treated Prevalent Cases of HS in the 7MM (2017-2030)
  • Figure 14 Total Prevalent Cases of HS in the United States (2017-2030)
  • Figure 15 Gender-Specific Prevalent Cases of HS in the United States (2017-2030)
  • Figure 16 Age-Specific Prevalent Cases of HS in the United States (2017-2030)
  • Figure 17 Stage-Specific Prevalent cases of HS in the United States (2017-2030)
  • Figure 18 Treated Prevalent Cases of HS in the United States (2017-2030)
  • Figure 19 Total Prevalent Cases of HS in Germany (2017-2030)
  • Figure 20 Gender-Specific Prevalent Cases of HS in Germany (2017-2030)
  • Figure 21 Age-Specific Prevalent Cases of HS in Germany (2017-2030)
  • Figure 22 Stage-Specific Prevalent cases of HS in Germany (2017-2030)
  • Figure 23 Treated Prevalent Cases of HS in Germany (2017-2030)
  • Figure 24 Total Diagnosed Prevalent Cases of HS in France (2017-2030)
  • Figure 25 Gender-Specific Prevalent Cases of HS in France (2017-2030)
  • Figure 26 Age-Specific Prevalent Cases of HS in France (2017-2030)
  • Figure 27 Stage-Specific Prevalent cases of HS in France (2017-2030)
  • Figure 28 Treated Prevalent Cases of HS in France (2017-2030)
  • Figure 29 Total Diagnosed Prevalent Cases of HS in Italy (2017-2030)
  • Figure 30 Gender-Specific Prevalent Cases of HS in Italy (2017-2030)
  • Figure 31 Age-Specific Prevalent Cases of HS in Italy (2017-2030)
  • Figure 32 Stage-Specific Prevalent cases of HS in Italy (2017-2030)
  • Figure 33 Treated Prevalent Cases of HS in Italy (2017-2030)
  • Figure 34 Total Diagnosed Prevalent Cases of HS in Spain (2017-2030)
  • Figure 35 Gender-Specific Prevalent Cases of HS in Spain (2017-2030)
  • Figure 36 Age-Specific Prevalent Cases of HS in Spain (2017-2030)
  • Figure 37 Stage-Specific Prevalent cases of HS in Spain (2017-2030)
  • Figure 38 Treated Prevalent Cases of HS in Spain (2017-2030)
  • Figure 39 Total Diagnosed Prevalent Cases of HS in the United Kingdom (2017-2030)
  • Figure 40 Gender-Specific Prevalent Cases of HS in the United Kingdom (2017-2030)
  • Figure 41 Age-Specific Prevalent Cases of HS in the United Kingdom (2017-2030)
  • Figure 42 Stage-Specific Prevalent cases of HS in the United Kingdom (2017-2030)
  • Figure 43 Treated Prevalent Cases of HS in the United Kingdom (2017-2030)
  • Figure 44 Total Diagnosed Prevalent Cases of HS in Japan (2017-2030)
  • Figure 45 Gender-Specific Prevalent Cases of HS in Japan (2017-2030)
  • Figure 46 Age-Specific Prevalent Cases of HS in Japan (2017-2030)
  • Figure 47 Stage-Specific Prevalent cases of HS in Japan (2017-2030)
  • Figure 48 Treated Prevalent Cases of HS in Japan (2017-2030)